Minerva Neurosciences (NERV) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $2.35, -2.89% vs the prior close of $2.42.
- Volume 85.60K shares, 0.4x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
NERV dips 2.9% to $2.35. Closed at $2.35, -2.89% vs the prior close of $2.42. Day range $2.30–$2.47, opened at $2.42.
NERV daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — NERV dips 2.9% to $2.35
- Closed at $2.35, -2.89% vs the prior close of $2.42. Day range $2.30–$2.47, opened at $2.42.
- Volume was 85.60K shares, 0.4x its 50-day average of 193.64K — lighter than usual.
- Price is -39.9% vs its 50-day average ($3.91) and -53.0% vs its 200-day average ($5.00).
- 52-week range $2.28–$12.46; today's close sits at 1% of that range, 81.1% below the 52-week high.
Oct 15, 2026 — NERV rises 3.0% to $2.42
- Closed at $2.42, +2.98% vs the prior close of $2.35. Day range $2.28–$2.49, opened at $2.37.
- Volume was 159.40K shares, 0.8x its 50-day average of 192.78K.
- Price is -38.8% vs its 50-day average ($3.95) and -51.7% vs its 200-day average ($5.01).
- 52-week range $2.28–$12.46; today's close sits at 1% of that range, 80.6% below the 52-week high.
Oct 14, 2026 — NERV slides 6.6% to $2.35, a 52-week low, 6 down days in a row
- Closed at $2.35, -6.56% vs the prior close of $2.52. Day range $2.31–$2.57, opened at $2.51.
- Volume was 254.30K shares, 1.3x its 50-day average of 189.39K.
- Price is -41.1% vs its 50-day average ($3.99) and -53.2% vs its 200-day average ($5.02).
- 52-week range $2.31–$12.46; today's close sits at 0% of that range, 81.1% below the 52-week high.
- That makes 6 straight losses.
Oct 13, 2026 — NERV slides 13.0% to $2.52, a 6-month low, 5 down days in a row
- Closed at $2.52, -12.98% vs the prior close of $2.89. Day range $2.51–$3.08, opened at $2.88.
- Volume was 185.50K shares, 1.0x its 50-day average of 187.35K.
- Price is -37.5% vs its 50-day average ($4.02) and -50.0% vs its 200-day average ($5.03).
- 52-week range $2.24–$12.46; today's close sits at 3% of that range, 79.8% below the 52-week high.
- That makes 5 straight losses.
Oct 12, 2026 — NERV slides 9.1% to $2.89, a 6-month low, 4 down days in a row
- Closed at $2.89, -9.12% vs the prior close of $3.18. Day range $2.87–$3.23, opened at $3.18.
- Volume was 84.90K shares, 0.5x its 50-day average of 187.07K — lighter than usual.
- Price is -28.7% vs its 50-day average ($4.05) and -42.6% vs its 200-day average ($5.03).
- 52-week range $2.24–$12.46; today's close sits at 6% of that range, 76.8% below the 52-week high.
- That makes 4 straight losses.
Oct 9, 2026 — NERV dips 1.2% to $3.18, a 6-month low, 3 down days in a row
- Closed at $3.18, -1.24% vs the prior close of $3.22. Day range $3.13–$3.31, opened at $3.23.
- Volume was 192.50K shares, 1.0x its 50-day average of 185.06K.
- Price is -22.0% vs its 50-day average ($4.08) and -36.9% vs its 200-day average ($5.04).
- 52-week range $2.24–$12.46; today's close sits at 9% of that range, 74.5% below the 52-week high.
- That makes 3 straight losses.
Oct 8, 2026 — NERV dips 1.5% to $3.22, a 6-month low
- Closed at $3.22, -1.53% vs the prior close of $3.27. Day range $3.13–$3.37, opened at $3.25.
- Volume was 143.30K shares, 0.8x its 50-day average of 185.46K.
- Price is -21.3% vs its 50-day average ($4.09) and -36.1% vs its 200-day average ($5.04).
- 52-week range $2.24–$12.46; today's close sits at 10% of that range, 74.2% below the 52-week high.
Oct 7, 2026 — NERV slides 4.7% to $3.27
- Closed at $3.27, -4.66% vs the prior close of $3.43. Day range $3.25–$3.46, opened at $3.36.
- Volume was 106.50K shares, 0.6x its 50-day average of 187.31K — lighter than usual.
- Price is -20.4% vs its 50-day average ($4.11) and -35.2% vs its 200-day average ($5.05).
- 52-week range $2.12–$12.46; today's close sits at 11% of that range, 73.8% below the 52-week high.
Oct 6, 2026 — NERV jumps 3.3% to $3.43, 3 up days in a row
- Closed at $3.43, +3.31% vs the prior close of $3.32. Day range $3.28–$3.49, opened at $3.38.
- Volume was 105.30K shares, 0.6x its 50-day average of 188.57K — lighter than usual.
- Price is -16.9% vs its 50-day average ($4.13) and -32.1% vs its 200-day average ($5.05).
- 52-week range $2.08–$12.46; today's close sits at 13% of that range, 72.5% below the 52-week high.
- That makes 3 straight gains.
Oct 5, 2026 — NERV rises 1.2% to $3.32
- Closed at $3.32, +1.22% vs the prior close of $3.28. Day range $3.19–$3.56, opened at $3.30.
- Volume was 72.40K shares, 0.4x its 50-day average of 190.57K — lighter than usual.
- Price is -19.9% vs its 50-day average ($4.14) and -34.3% vs its 200-day average ($5.05).
- 52-week range $2.08–$12.46; today's close sits at 12% of that range, 73.4% below the 52-week high.
Oct 2, 2026 — NERV rises 1.5% to $3.28
- Closed at $3.28, +1.55% vs the prior close of $3.23. Day range $3.22–$3.37, opened at $3.29.
- Volume was 57.00K shares, 0.3x its 50-day average of 192.14K — lighter than usual.
- Price is -21.1% vs its 50-day average ($4.16) and -35.1% vs its 200-day average ($5.06).
- 52-week range $2.08–$12.46; today's close sits at 12% of that range, 73.7% below the 52-week high.
NERV latest news & SEC filings
Every SEC filing by or about NERV in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 20, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 20, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 7, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: $17.47M (prior year -$3.26M) (swung to profit vs Jun 30, 2025)
- Diluted EPS: -$0.14 (prior year -$0.43) (loss narrowed vs Jun 30, 2025)
Aug 7, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 3, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 8, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade NERV
- Last results release: Aug 7, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Mar 11, 2026, Mar 26, 2015. Based on that rhythm, the next report is likely around Nov 6, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.41% (largest 13.0%). That is a volatile stock.
- Liquidity: about 118.23K shares (≈$277.84K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $2.35 vs a range of $2.28–$12.46 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Aug 12, 2026; 10-Q Aug 7, 2026; 8-K Aug 7, 2026.
- Share count: 47.75M shares outstanding (Aug 4, 2026), +582.8% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
NERV market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 2.42 | 2.47 | 2.30 | 2.35 | 85.60K |
| Oct 15, 2026 | 2.37 | 2.49 | 2.28 | 2.42 | 159.40K |
| Oct 14, 2026 | 2.51 | 2.57 | 2.31 | 2.35 | 254.30K |
| Oct 13, 2026 | 2.88 | 3.08 | 2.51 | 2.52 | 185.50K |
| Oct 12, 2026 | 3.18 | 3.23 | 2.87 | 2.89 | 84.90K |
| Oct 9, 2026 | 3.23 | 3.31 | 3.13 | 3.18 | 192.50K |
| Oct 8, 2026 | 3.25 | 3.37 | 3.13 | 3.22 | 143.30K |
| Oct 7, 2026 | 3.36 | 3.46 | 3.25 | 3.27 | 106.50K |
| Oct 6, 2026 | 3.38 | 3.49 | 3.28 | 3.43 | 105.30K |
| Oct 5, 2026 | 3.30 | 3.56 | 3.19 | 3.32 | 72.40K |
| Oct 2, 2026 | 3.29 | 3.37 | 3.22 | 3.28 | 57.00K |
| Oct 1, 2026 | 3.35 | 3.35 | 3.17 | 3.23 | 89.20K |
| Sep 30, 2026 | 3.37 | 3.48 | 3.31 | 3.35 | 79.30K |
| Sep 29, 2026 | 3.50 | 3.50 | 3.27 | 3.35 | 33.30K |
| Sep 28, 2026 | 3.37 | 3.43 | 3.23 | 3.40 | 62.30K |
| Sep 25, 2026 | 3.46 | 3.50 | 3.37 | 3.40 | 103.30K |
| Sep 24, 2026 | 3.51 | 3.61 | 3.33 | 3.45 | 147.50K |
| Sep 23, 2026 | 3.78 | 3.78 | 3.45 | 3.49 | 130.50K |
| Sep 22, 2026 | 3.71 | 3.86 | 3.66 | 3.81 | 123.90K |
| Sep 21, 2026 | 3.72 | 3.81 | 3.59 | 3.68 | 148.60K |
About Minerva Neurosciences
Minerva Neurosciences (NERV) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BURLINGTON, MA. State of incorporation: MA. Fiscal year ends December 31. SEC CIK 1598646.
NERV board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Hans Peter Hasler | Director | Jun 5, 2026 |
| Inderjit Kaul | Director | Aug 3, 2026 |
| David Kupfer | Director | Jun 5, 2026 |
| Fouzia Laghrissi-Thode | Director | Jun 5, 2026 |
| Remy Luthringer | CEO | Jun 5, 2026 |
| Heek G Jan Van | Director | Jun 5, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Frederick W Ahlholm | SVP, CFO and Secretary | Jun 5, 2026 |
| Anthony Aliquo | Chief Accounting Officer | Aug 20, 2026 |
| Remy Luthringer | CEO | Jun 5, 2026 |
| James Joseph O'Connor | Chief Business Officer and GC | Apr 22, 2026 |
| Geoff Race | President | Dec 23, 2025 |
| Joseph H. Reilly | Chief Operating Officer | Aug 20, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
NERV financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-293.42M | -34.67 | $-13.51M |
| Dec 31, 2024 | $0 | $1.44M | 0.19 | $-19.55M |
| Dec 31, 2023 | $0 | $-30.01M | -4.61 | $-14.78M |
| Dec 31, 2022 | $0 | $-32.11M | -6.01 | $-24.65M |
| Dec 31, 2021 | $0 | $-49.91M | -9.35 | $-24.60M |
Latest balance sheet: total assets $95.09M, total liabilities $296.65M, cash $24.65M (as of Jun 30, 2026).
NERV earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 7, 2026 | 8-K Item 2.02 (results) | $4.27 |
| May 5, 2026 | 8-K Item 2.02 (results) | $6.25 |
| Mar 11, 2026 | 8-K Item 2.02 (results) | $7.30 |
| Mar 26, 2015 | 8-K Item 2.02 (results) | — |
| Nov 6, 2014 | 8-K Item 2.02 (results) | — |
| Aug 7, 2014 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on NERV
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.